Cancer Discov. 2020 Nov;10(11):1617. doi: 10.1158/2159-8290.CD-NB2020-089. Epub 2020 Oct 1.
Evidence continues to grow that KRAS, once considered an "undruggable" target, can be targeted successfully in non-small cell lung cancer. In a phase I trial, the KRAS inhibitor sotorasib elicited responses in about a third of patients with the disease and was generally well tolerated.
越来越多的证据表明，KRAS这个曾经被认为是“不可成药”的靶点，在非小细胞肺癌中可以被成功靶向。在一项I期试验中，KRAS抑制剂索托拉西布在约三分之一的该疾病患者中引发了反应，并且总体耐受性良好。
